Why the study?
Does CLC-3000 improve vasodilation and prevent nitrate tolerance compared to pioglitazone or classical nitrates in preclinical models?
Does CLC-3000 improve vasodilation and prevent nitrate tolerance compared to pioglitazone or classical nitrates in preclinical models?
CLC-3000, a novel pioglitazone-nitrate hybrid, demonstrates potent vasodilation and antithrombotic activity without inducing nitrate tolerance or endothelial dysfunction in preclinical models.
Answers are grounded in this paper and cite their sources.
Warrants further preclinical testing of this hybrid; leaves open translation to human cardiovascular therapy.
BACKGROUND/AIMS: Organic nitrates represent a group of nitrovasodilators that are clinically used for the treatment of ischemic heart disease. The new compound CLC-3000 is an aminoethyl nitrate (AEN) derivative of pioglitazone, a thiazolidinedione antidiabetic agent combining the peroxisome proliferator-activated receptor γ agonist activity of pioglitazone with the NO-donating activity of the nitrate moiety. METHODS: In vitro and in vivo characterization was performed by isometric tension recording, platelet function, bleeding time and detection of oxidative stress. RESULTS: In vitro, CLC-3000 displayed more potent vasodilation than pioglitazone alone or classical nitrates. In vitro, some effects on oxidative stress parameters were observed. Authentic AEN or the AEN-containing linker CLC-1275 displayed antiaggregatory effects. In vivo treatment with CLC-3000 for 7 days did neither induce endothelial dysfunction nor nitrate tolerance nor oxidative stress. Acute or chronic administration of AEN increased the tail vein bleeding time in mice. CONCLUSION: In summary, the results of these studies demonstrate that CLC-3000 contains a vasodilative and antithrombotic activity that is not evident with pioglitazone alone, and that 7 days of exposure in vivo showed no typical signs of nitrate tolerance, endothelial dysfunction or other safety concerns in Wistar rats.
No takes yet. Share an insight, caveat, or question.
Knorr et al. (2014) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: